Faslodex 250 mg solution for injection. clinical trials
6 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
This study looks at new drug combinations for advanced breast cancer that has spread. It focuses on a type of breast cancer called 'HER2-low'. Doctors want to see if these combinations are safe, how they work in the body, and if they can help shrink tumours.
For: Metastatic Breast CancerBelgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C4391022 - AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY
This study looks at a new drug (PF-07220060) combined with a standard breast cancer treatment (Fulvestrant). It's for advanced hormone receptor-positive, HER2-negative breast cancer that has grown after previous CDK 4/6 inhibitor treatment. Researchers want to see if the new combination works better.
For: Hormone receptor-positive · her2-negative advanced/metastatic breast cancerSweden · Czechia · Bulgaria - Ongoing, recruitingTherapeutic exploratory (Phase II)
CT7001_002 (SUMIT-BC) - An open-label Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant with or without Samuraciclib in Participants with Metastatic or Locally Advanced Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
This study is looking at a new drug (Samuraciclib) combined with a standard breast cancer treatment (Fulvestrant) for advanced or spread hormone-sensitive breast cancer. Doctors want to see if this new combination works better at shrinking tumours or stopping them from growing for a longer time.
For: metastatic or locally advanced Hormone Receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancerSpain · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
C4251003- A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations.
This study is looking at a new combination of medicines for people with certain advanced cancers where previous treatments haven't worked well. It aims to see how many people respond to the treatment.
For: Previously Treated · Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsGermany · Belgium · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant
This study is looking at a new treatment for certain types of advanced breast cancer. It combines a new drug (ZW25) with existing medicines (palbociclib and fulvestrant) to see if it's safe and effective for patients whose cancer has spread or can't be removed by surgery.
For: Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive · HR-positive breast cancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in combination with PD-0332991 (Palbociclib) as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of adjuvant endocrine therapy and remained disease free for more than 12 months following its completion or have de novo metastatic disease. "The FLIPPER Study"
This study, called "The FLIPPER Study," is looking at new treatments for women with breast cancer that has spread. It compares a standard drug (Faslodex) with a new combination of Faslodex and another drug (Palbociclib) to see if it works better at stopping the cancer from growing.
For: Metastatic breast cancerSpain · Ireland